- Home
- CVBF vs GLPG Comparison
CVBF vs GLPG Comparison
Compare CVBF & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVBF
- GLPG
- Stock Information
- Founded
- CVBF 1974
- GLPG 1999
- Country
- CVBF United States
- GLPG Belgium
- Employees
- CVBF N/A
- GLPG N/A
- Industry
- CVBF Major Banks
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- CVBF Finance
- GLPG Health Care
- Exchange
- CVBF Nasdaq
- GLPG Nasdaq
- Market Cap
- CVBF 2.6B
- GLPG 2.1B
- IPO Year
- CVBF N/A
- GLPG 2005
- Fundamental
- Price
- CVBF $20.21
- GLPG $33.24
- Analyst Decision
- CVBF Buy
- GLPG Sell
- Analyst Count
- CVBF 4
- GLPG 3
- Target Price
- CVBF $23.25
- GLPG $26.00
- AVG Volume (30 Days)
- CVBF 630.8K
- GLPG 162.5K
- Earning Date
- CVBF 10-22-2025
- GLPG 10-29-2025
- Dividend Yield
- CVBF 4.09%
- GLPG N/A
- EPS Growth
- CVBF N/A
- GLPG N/A
- EPS
- CVBF 1.46
- GLPG N/A
- Revenue
- CVBF $507,999,000.00
- GLPG $323,674,692.00
- Revenue This Year
- CVBF N/A
- GLPG $1.77
- Revenue Next Year
- CVBF $5.77
- GLPG N/A
- P/E Ratio
- CVBF $13.40
- GLPG N/A
- Revenue Growth
- CVBF N/A
- GLPG 5.43
- 52 Week Low
- CVBF $16.01
- GLPG $22.36
- 52 Week High
- CVBF $24.58
- GLPG $33.86
- Technical
- Relative Strength Index (RSI)
- CVBF 54.64
- GLPG 58.22
- Support Level
- CVBF $19.46
- GLPG $31.49
- Resistance Level
- CVBF $20.53
- GLPG $33.63
- Average True Range (ATR)
- CVBF 0.44
- GLPG 0.68
- MACD
- CVBF -0.05
- GLPG 0.01
- Stochastic Oscillator
- CVBF 60.48
- GLPG 85.82
About CVBF CVB Financial Corporation
CVB Financial Corp is the holding company for Citizens Business Bank. Citizens Business Bank offers banking, lending, and investing services. It provides a full complement of lending products, including commercial, agribusiness, consumer, SBA, real estate, and construction loans, as well as equipment and vehicle leasing. Commercial products include lines of credit and other working capital financing, accounts receivable lending and letters of credit.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.